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Abstract
Background: Intermittent preventive treatment of malaria in children (IPTc) is a promising new approach to the control of
malaria in areas of seasonal malaria transmission but it is not known if IPTc adds to the protection provided by an
insecticide-treated net (ITN).
Methods and Findings: An individually randomised, double-blind, placebo-controlled trial of seasonal IPTc was conducted
in Burkina Faso in children aged 3 to 59 months who were provided with a long-lasting insecticide-treated bednet (LLIN).
Three rounds of treatment with sulphadoxine pyrimethamine plus amodiaquine or placebos were given at monthly
intervals during the malaria transmission season. Passive surveillance for malaria episodes was established, a cross-sectional
survey was conducted at the end of the malaria transmission season, and use of ITNs was monitored during the intervention
period. Incidence rates of malaria were compared using a Cox regression model and generalized linear models were fitted
to examine the effect of IPTc on the prevalence of malaria infection, anaemia, and on anthropometric indicators. 3,052
children were screened and 3,014 were enrolled in the trial; 1,505 in the control arm and 1,509 in the intervention arm.
Similar proportions of children in the two treatment arms were reported to sleep under an LLIN during the intervention
period (93%). The incidence of malaria, defined as fever or history of fever with parasitaemia $5,000/ml, was 2.88 (95%
confidence interval [CI] 2.70–3.06) per child during the intervention period in the control arm versus 0.87 (95% CI 0.78–0.97)
in the intervention arm, a protective efficacy (PE) of 70% (95% CI 66%–74%) (p,0.001). There was a 69% (95% CI 6%–90%)
reduction in incidence of severe malaria (p=0.04) and a 46% (95% CI 7%–69%) (p=0.03) reduction in the incidence of all-
cause hospital admissions. IPTc reduced the prevalence of malaria infection at the end of the malaria transmission season by
73% (95% CI 68%–77%) (p,0.001) and that of moderately severe anaemia by 56% (95% CI 36%–70%) (p,0.001). IPTc
reduced the risks of wasting (risk ratio [RR]=0.79; 95% CI 0.65–1.00) (p=0.05) and of being underweight (RR=0.84; 95% CI
0.72–0.99) (p=0.03). Children who received IPTc were 2.8 (95% CI 2.3–3.5) (p,0.001) times more likely to vomit than
children who received placebo but no drug-related serious adverse event was recorded.
Conclusions: IPT of malaria provides substantial protection against malaria in children who sleep under an ITN. There is now
strong evidence to support the integration of IPTc into malaria control strategies in areas of seasonal malaria transmission.
Trial Registration: ClinicalTrials.gov NCT00738946
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Significant efforts have been made in recent years to improve
malaria control. However, malaria still remains a major public
health problem in sub-Saharan Africa, responsible for about
800,000 deaths annually [1], and existing malaria control
strategies provide only partial protection. The pressing need for
new malaria control tools has led to evaluation of the strategy of
intermittent preventive treatment (IPT) of malaria. IPT involves
administration of antimalarial drugs at defined time intervals to
individuals regardless of whether they are known to be infected
with malaria to prevent morbidity and mortality from the infection
[2]. IPT was initially recommended for pregnant women involving
the administration of at least two doses of sulphadoxine
pyrimethamine (SP) during antenatal visits after the first trimester
of pregnancy. Recently the strategy was extended to infants (IPTi)
with the administration of three doses of an antimalarial drug
during the expanded programme of immunization (EPI) visits [3].
An Institute of Medicine report [4] indicated that IPTi is
associated with a 30% (95% confidence interval [CI] 20%–39%)
reduction in the incidence of clinical malaria. However in areas of
seasonal malaria transmission, such as the Sahel and the sub-
Sahelian regions of Africa, the main burden of malaria is in
children under 5 y of age [5]. The strategy of IPT of malaria in
children (IPTc) was designed for regions where malaria transmis-
sion is seasonal [6].
IPTc involves the administration of two to three doses of
antimalarial drug during the high malaria transmission season.
IPTc with artesunate (AS) plus amodiaquine (AQ) given to
children aged 3–59 mo old on three occasions at monthly intervals
during the malaria transmission season led to an 86% reduction in
the incidence of clinical episodes of malaria in Senegal [6]. In an
earlier study conducted in Mali, IPTc with sulphadoxine
pyrimethamine (SP), administered on two occasions during the
malaria transmission season with a 2-mo interval between
treatments, reduced the incidence of malaria in children aged
6 mo to 10 y by 65% [7]. Similar findings were reported in Ghana
in an area with perennial malaria transmission but a major
seasonal peak, where six monthly rounds of administration of
AS+AQ led to a 69% decrease in the incidence of malaria in
children [8]. IPTc was safe and well tolerated in each of these
studies [6–8], and no evidence of a rebound in the incidence of
malaria was observed in the year after the intervention was
stopped [6].
Insecticide-treated bednets (ITNs) provide at least 50%
protection against morbidity from malaria [9] and are currently
the cornerstone of malaria control in many countries in sub-
Saharan Africa, although coverage with ITNs is still low in some
countries. For example, in Burkina Faso it was estimated that
between 2003 and 2006, fewer than 20% of households owned an
ITN and less than 10% of children aged below 5 y of age slept
under an ITN [1]. However, strenuous efforts are being made to
increase coverage in endemic areas and in Burkina Faso, the
National Malaria Control Programme (NMCP) has started
procedures to purchase about 6 million long-lasting insecticide-
treated bednets (LLINs).
The successful trials of IPTc described above were conducted in
areas with relatively low coverage of ITNs. Thus, it is not known
whether IPTc will be as effective in children who sleep under an
ITN as has been found in communities where ITN usage is low.
To determine this difference, we have conducted a randomised,
placebo-controlled trial of IPTc with SP + AQ in children who
slept under an ITN in an area of seasonal malaria transmission in
Burkina Faso. A parallel study has been conducted in Mali
employing a very similar protocol [10], and it was planned to
involve a third site from Ghana. However, this site could not
participate because of delays in getting regulatory approval for the
use of SP + AQ for IPTc from the Ghana Food and Drug Board.
SP + AQ combination was chosen because this drug
combination is cheap and remains highly efficacious for malaria
treatment in Burkina Faso [11,12]. SP was considered as a second-
line drug for the treatment of malaria before the introduction of
artermisinin-based combination therapy, but the drug was seldom
used, as was AQ. A previous study in Senegal showed that the SP
+ AQ combination was very effective for reducing the incidence of
clinical malaria when used for IPT in children [13]. However, the
main concern with this drug combination is the increased risk of
vomiting associated with AQ.
Materials and Methods
The protocol of the trial (Text S1), protocol amendment (Text
S2), and CONSORT checklist (Text S3) are available as
supporting information.
Study Design
An individually randomised, double-blind, placebo-controlled
trial was carried out during the 2008 malaria transmission season
to evaluate the efficacy of IPTc in children who slept under an
LLIN. All children enrolled in the trial (aged 3–59 mo) were given
an LLIN at the start of the study and their family instructed in the
use of the net. Children were then randomised to receive three
courses of IPTc with SP plus AQ or placebos given at monthly
intervals during the peak malaria transmission season. The
combination of SP plus AQ was chosen for the trial following a
pilot study conducted in the study villages in 2006, which showed
that this combination was effective at treating uncomplicated
falciparum malaria (Text S4). The incidence of malaria was
monitored throughout the malaria season and a cross-sectional
survey was performed at its end.
Ethical Approval
Ethical clearance for the trial was obtained from the Health
Ethics Committee of Burkina Faso and from the London School of
Hygiene and Tropical Medicine ethics committee. The study’s
objectives and methods were explained to each study community
prior to the start of the trial and written informed consent was
obtained from care givers of children before enrolment in the
study. The trial was monitored by an independent Data Safety and
Monitoring Board (DSMB).
Study Area
The study was carried out in four villages (Laye, Niou, Sao, and
Toeghin) in Bousse ´ health district, Kourweogo province, approx-
imately 40 km northwest of Ouagadougou. The climate in the
study area is characteristic of the Sudanese savannah with a dry
season from November to June and a rainy season from July to
October. The main malaria vectors are Anopheles gambiae s.s., An.
Arabiensis, and An. funestus [14]. Malaria transmission is high but
seasonal. In 2002, the entomological inoculation rate (EIR) was
estimated to be 173 infective bites per person per year [15] with a
peak in September. Plasmodium falciparum is responsible for more
than 95% of malaria infections in the study area.
Study Endpoints
The primary endpoint of the study was the incidence of clinical
malaria defined as the presence of fever (axillary temperature
$37.5uC) or a history of fever in the past 24 h, the absence of any
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asexual parasites of P. falciparum per microlitre. This threshold has
previously been shown to be of value in differentiating symptom-
atic malaria from other causes of fever with coincidental
parasitaemia [16]. The secondary endpoints were: (1) the
incidence of clinical malaria defined as the presence of fever or
history of fever, the absence of any other obvious cause of fever,
and the presence of P. falciparum asexual parasites at any density;
(2) the incidence of severe malaria defined according to WHO
criteria [17]; (3) the prevalence of anaemia at the end of malaria
transmission season; (4) the prevalence of parasitaemia at the end
of the malaria transmission season; (5) the prevalence of wasting,
stunting, and being underweight at the end of malaria transmission
season; (6) the incidence of all-cause hospital admissions during the
surveillance period.
Hospital admission was defined as any event that involved a
child staying at a hospital or health centre for at least 24 h for
medical care. Anaemia was defined as a haemoglobin (Hb)
concentration ,11 g/dl, moderately severe anaemia as an Hb
,8 g/dl, and severe anaemia as an Hb ,5 g/dl. Wasting (acute
malnutrition), stunting (chronic malnutrition), and underweight
(chronic and/or acute malnutrition) were assessed using the WHO
child growth standards [18]. Children with weight-for-age z-scores
(WAZ) ,22 were classified as underweight and children with
height-for-age z-scores (HAZ) ,22 were classified as stunted.
Children with weight-for-height z-scores (WHZ) ,22 were
classified as wasted.
Sample Size
We first calculated the sample size required to provide the trial
with 90% power to detect a 20% reduction in the incidence of
clinical malaria in the IPTc arm of the study at the 5% level of
significance. We assumed that the incidence of clinical malaria in
children under 5 y of age in the study area, in the absence of any
intervention, would be in the range of 1.0–2.0 episodes per year.
We further assumed that in children protected by an ITN, the
incidence of malaria would be reduced by 50% to 0.5–1.0 episodes
per year. To detect a 20% reduction in the incidence of malaria,
from 0.5 to 0.4 episode per year, in children who received IPTc,
and allowing for a 20% loss to follow-up, we estimated that
approximately 1,000 children would be required in each study
arm. We further estimated that a study with this sample size would
have at least 90% power to detect a 20% reduction in the
prevalence of malaria infection (from 50% to 40%) at the end of
the malaria transmission season [19].
With a sample size of 1,000 children per arm, the study was not
powered to detect an impact on the incidence of severe malaria or
hospitalization with malaria. We estimated that the rate of hospital
admissions with malaria would be in the range of 20 to 60 per
1,000 children under 5 y of age. Assuming a rate of 40 per 1,000,
approximately 3,000 children would be required per treatment
arm to detect a 50% reduction in hospital admissions with severe
malaria (from 40 to 20 per 1,000), assuming 20% loss to follow-up.
A protocol amendment was made to increase the sample size after
the site in Ghana was dropped from the trial (Text S2). Therefore,
the sample size was increased to 1,500 children per treatment arm
in our trial and in a parallel study conducted in Mali [10], with the
intention of combining results from the two trials to investigate the
impact of IPTc on the severe malaria endpoint.
Enrolment and Randomisation
Study villages were located in an area in which a demographic
surveillance system (DSS) was implemented until 2002. We used
the DSS database to identify and select four villages, each with a
health centre and with a combined population of 3,600 to 3,800
children aged 3–59 mo. The aim was to sample about 500
children from the DSS database for the baseline prevalence of
genetic markers of resistance to SP and AQ and screen the
remaining children for enrolment in the trial, allowing for the
possibility that a fraction of these children would not meet the
inclusion criteria. Therefore, all children aged 3–59 mo in the four
selected study villages were enumerated before the start of the
intervention and screened for eligibility to participate in the study.
The child’s weight and height were measured. To be eligible, a
child had to fulfil the following inclusion criteria: body weight of at
least 5 kg, resident in one of the study villages with no plan to
move out of the study area during the intervention period, no signs
or symptoms of severe chronic illness, absence of signs of severe
malnutrition, and signed informed consent obtained from the care
giver. Children with a history of sensitivity to any antimalarial
drug were excluded. Children diagnosed with clinical malaria
during screening were randomised and then treated according to
local guidelines.
Eligible children were randomised to the intervention or control
group using sealed envelopes. The randomisation list was prepared
in three strata for children weighing 5–9 kg, 10–18 kg, and $19 kg
by a statistician, and treatment group was assigned in each stratum
in a 1:1 ratio in permuted blocks of size 10. Blocks were not split
across villages. Envelopes in each stratum were assigned in strict
numerical order by the research team. When the child was enrolled,
the child’s name and randomization code were written on the
outside of the envelope before the envelope was opened. Each child
was given an identification (ID) card to facilitate follow-up.
LLINs
All screened children were given an LLIN (PermaNet; www.
vestergaard-frandsen.com) regardless of their eligibility status.
LLINs were marked to differentiate them from already existing
nets and care givers were advised on how to use them.
Drugs and Packaging
A course of IPTc comprised a single treatment with SP and
three daily doses of AQ, the first dose of AQ being given with SP.
The target dose for SP was 25 mg of sulphadoxine and 1.25 mg
pyrimethamine per kg, and that for AQ was 10 mg per kg daily
given for 3 d. Active SP and AQ tablets and matching placebos
were obtained from KINAPHARMA Limited. To achieve as
accurate a dosing schedule as possible, whilst maintaining
simplicity in delivery and avoiding the need to break tablets,
three sets of SP and AQ tablets were manufactured. SP tablets for
children in the 5–9 kg weight group contained 175 mg of
sulphadoxine and 8.75 mg of pyrimethamine per tablet, those
for children in the 10–18 kg group contained 350 mg of
sulphadoxine and 17.5 mg of pyrimethamine, and those for
children 19 kg or more contained 550 mg sulphadoxine and
26.25 mg of pyrimethamine. AQ tablets for children in each of the
three weight categories contained daily doses of 70, 140, and
220 mg of AQ, respectively. This regimen gave an AQ dose of
7.8–14 mg/kg/d, which is within the recommended therapeutic
range of 7–15 mg/kg/d [20].
Drugs for each course of treatment were packaged in small,
sealable plastic bags labelled with a child’s randomisation code and
course number and placed in an envelope labelled with the child’s
randomisation code and the village number. A fourth plastic bag
containing replacement doses for SP and AQ was included in each
envelope. Samples of active and placebo tablets from different
containers provided by the manufacturer were analysed at the
London School of Hygiene and Tropical Medicine to confirm
Intermittent Preventive Treatment
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the randomisation and packing procedure. Drug content and
solubility met international standards.
Intervention
In each village, IPTc was administered at a convenient location
close to the health centre and supervised by the research team.
The research team and the care givers were blinded as to which
group of children received active drugs or placebos. Treatment
courses were given in August, September, and October during the
peak malaria transmission season, with 1 mo intervals between
treatments. Active drugs and placebos were crushed and mixed
with sugary water to mask the bitterness of AQ and to improve
drug intake. Children were observed for 30 min after treatment. If
a child vomited or regurgitated the drug within this period, a
second treatment was given. If the child vomited the second
treatment no further replacement dose was given for that
treatment course but the child was asked to attend the next day
or the next round of treatment.
Children were examined before administration of the first dose
of each treatment round and a rapid diagnostic test (RDT;
OPTIMAL IT; Diamed AG) for malaria was performed for
children with fever or a history of fever in the previous 24 h. If the
RDT was negative, the child was given IPTc and appointments
were made for subsequent IPTc visits before referral to the health
centre to check for illnesses other than malaria. If the RDT was
positive, a blood film was prepared and the child was treated with
Coartem by the research team; children with severe malaria were
referred to the health centres for treatment with quinine according
to local guidelines. In such situations, IPTc was not given but the
care giver was invited to bring the child back for the next round of
IPTc.
Passive Surveillance for Clinical Malaria
Passive surveillance for malaria and other illnesses was
established soon after the enrolment of children. Health centres
were supplied with lists of children enrolled in the study and with
equipment and consumables for the diagnosis of malaria and
anaemia. Care givers were asked to bring any child with fever to
the health centre together with the child’s ID card. The child’s
identity was verified against the list of enrolled children. Clinical
examination was then conducted and signs and symptoms of any
illness were recorded. An RDT was performed and if the test was
positive, thick and thin blood films were prepared and sent to the
CNRFP laboratory for microscopy. Coartem was not available at
the health centres, so on the basis of RDT test results, treatment
with AS+AQ was given if the child was suspected to have
uncomplicated malaria. If a child had signs or symptoms of severe
malaria, s/he was treated with quinine at the health centre or
referred to the district hospital according to local guidelines.
Children whose RDT was negative were examined for other
causes of fever and an appropriate treatment was administered if
required. A medically qualified member of the research team was
based at the district hospital with responsibility for follow-up of
study children who were referred to the district hospital. Full
treatment costs, and the cost of transportation to the district
hospital, were covered by the project.
Monitoring of Malaria Infection, Anaemia, and
Anthropometric Indicators
From mid-September to the end of November 2008, 150
enrolled children were randomly selected and surveyed each week
to monitor the prevalence of malaria infection. These children
were visited at home by nurses who measured the child’s
temperature, prepared thick and thin blood films for all children,
and completed data collection forms. Care givers were asked if the
child had had a fever within the last 24 h and whether the LLIN
allocated to them was still in the house. If the LLIN was present,
the care giver was asked if the child had slept under the net the
previous night. Children with measured or reported fever were
referred to the health centre for clinical examination and
treatment as described above.
A cross-sectional survey of all children enrolled in the study was
carried out 6 wk after the last course of IPTc had been given
(November 2008). Fever within the last 24 h was documented, and
axillary temperature, weight, and height were measured. Thick
and thin blood films and filter paper blood spots were prepared
and Hb concentration was measured. An RDT was performed if a
child had fever or a history of fever before referral to the health
centre for clinical examination and appropriate treatment.
Monitoring of Adverse Events
Clinical personnel participating in the trial were trained to
identify serious adverse events, including Stevens-Johnson syn-
drome, and to report them immediately to the local principal
investigator. Adverse events were monitored on the day of
administration of each dose and on the day after the last dose of
each treatment course by members of the research team who were
not involved in giving treatment. Questions were asked specifically
about the occurrence of any of the following adverse events: fever,
vomiting, diarrhoea, drowsiness, skin rash, coughing, loss of
appetite, and any other events that the child had experienced were
recorded. The duration and severity of adverse events was noted.
If a serious adverse event was observed or reported, the Data
Safety and Monitoring Board (DSMB) was notified of this event
within 72 h. Detailed information was collected on a separate case
report form and sent to the DSMB within 2 wk.
Monitoring of Drug Resistance
412 children not included in the main trial were randomly
selected from the census list to assess the baseline prevalence of
genetic markers of resistance to SP and AQ. Children were
clinically examined, and thick and thin blood films and filter paper
blood spots were prepared for malaria diagnosis and molecular
testing for drug resistance. These children were given an LLIN but
were not enrolled in the IPTc trial. Filter paper blood spots were
also collected 6 wk after the third course of treatment from
children involved in the trial to assess whether treatment with SP +
AQ had led to an increase in the prevalence of genetic markers of
resistance to these drugs. 312 of the filter papers collected from
746 children with P. falciparum parasitaemia during this survey
were randomly selected from the intervention and control arms for
PCR analysis. This sample size was based on results obtained from
the monitoring of resistance markers in an IPT trial in Senegalese
children [6]. In addition to monitoring the prevalence of genetic
markers of resistance to the study drugs, an in vivo study of the
efficacy of SP + AQ combination was undertaken in 252 children
with asymptomatic malaria in the year after the intervention (Text
S5).
Laboratory Methods
Thick and thin blood films were air dried and stained with 5%
Giemsa. Each slide was read by two laboratory technicians.
Asexual and sexual parasites were counted separately and species
differentiated. Malaria parasites were counted against 200 white
blood cells (WBC). A slide was declared negative only after reading
against 2,000 WBC without observation of a malaria parasite. The
Intermittent Preventive Treatment
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blood by multiplying the number of parasites counted by 8,000
and dividing by the number of WBC counted. In the event of a
discrepancy between the two readers in terms of the presence or
absence of malaria parasites, or if parasite densities differed by
more than 30%, the slide was reexamined by a third laboratory
technician. The arithmetic mean of the two final readings was
used as the final parasite density. If there was no agreement after
the third reading, the arithmetic mean of the three parasite
densities was used. External quality control of slide reading was
performed by the Malaria Diagnosis Centre of Excellence
(MDCoE) of the Walter Reed/Kenya Medical Research Institute,
in Kisumu (Kenya). The results showed that the quality of slide
reading was good with higher than 90% concordance on parasite
detection and species identification (Text S6).
Hb concentration was determined using a Hemocue 321
(Hemocue AB). The measurement was repeated for any Hb value
outside the manufacturer’s range (,5 g/dl and .18 g/dl). The
performance of the Hemocue was checked weekly with samples of
known Hb concentration.
DNA was extracted from filter papers collected before and after
the intervention to look for the presence of genetic markers of
resistance to SP and AQ. Nested PCR was performed to detect the
presence of mutations at codons 51, 59, and 108 of the dhfr gene and
at codons 437 and 540 of the dhps gene as described previously [21].
Restriction fragment length polymorphism was used to determine
the presence or absence of mutations at codon 76 of the P. falciparum
chloroquine transporter gene (pfcrt-76) and at codon 86 of the P.
falciparum multidrug resistance gene one (pfmdr1-86) [22].
Data Handling and Statistical Analysis
Double data entry by two independent data entry clerks was
performed. Data were entered using Microsoft Access. Consisten-
cy checks and audit trail programs were developed and the
database was cleaned and validated before analysis. The trial
analysis plan was approved by the DSMB. Data analysis was
performed using STATA version 10 (www.stata.com). Analyses
were performed on the basis of intention to treat (ITT).
Episodes of uncomplicated or severe malaria that occurred after
the first dose of IPTc and within 42 d of the third course of IPTc
administration were included in the analysis. The starting dates of
episodes of malaria meeting the primary or secondary definitions
above were identified. Child-days at risk were calculated and used
as the denominator for the estimation of the incidence of malaria.
Any child who experienced an episode of malaria and was treated
was not considered at risk for the next 21 d, which were deducted
from the child’s time at risk. Children who migrated, died, were
lost to follow-up, or were withdrawn from the study contributed to
the denominator up to the date of the event or up to the date when
they were seen for the last time by the research team.
The crude incidence rate ratio (IRR) for the effect of IPTc on
the incidence of malaria was estimated using Cox regression
models with robust standard errors to account for repeated
episodes within the same child. In secondary analyses, age, sex,
and village were included in the regression model as covariates to
obtain adjusted IRRs. Protective efficacy (PE) was derived from
the IRR as follows: PE=(1 2 IRR) 6100. Kaplan-Meier survival
curves were plotted to compare the times to the first episode of
malaria between children who received IPTc and those allocated
to the placebo arm.
Incidence rates of all-cause hospital admissions were estimated
as the number of all hospital admissions divided by the number of
child-days at risk computed as described above.
Malaria parasitaemia was defined as the presence of malaria
parasites irrespective of the developmental stage or species. The
presence or absence of malaria infection was coded as a binary
variable. Proportions of children with malaria parasites during
weekly visits and at the cross-sectional survey carried out 6 wk after
the last dose of IPTc were estimated for placebo and intervention
arms. The presence of anaemia or moderately severe anaemia 6 wk
after the last dose of IPTc was also coded as a binary variable. The
risk ratios (RRs) for malaria infection, anaemia, and moderately
severe anaemia among IPTc children compared with controls were
estimated using generalized linear models. Age, sex, and village
wereincluded as covariates to obtainadjusted RRs. The PE of IPTc
was calculated as follows: PE=(1 2 RR) 6100.
Anthropometric data collected 6 wk after the last course of IPTc
were transferred from STATA version 10 to WHO’s anthropo-
metric software [18] to obtain z-scores for weight-for-age (WAZ,
underweight), height-for-age (HAZ, stunting), and weight-for-
height (WHZ, wasting). Wasting, stunting, and being underweight
were defined according to the WHO child growth standards [18]
and coded as binary variables based on z-scores ,22. Proportions
of wasted, stunted, and underweight children were calculated and
compared between intervention and control arms by fitting a
generalized linear model to estimate crude and adjusted RRs.
Results
Baseline Characteristics
3,052 children were screened and 3,014 were enrolled in the
trial (Figure 1); 1,509 were allocated to the intervention group (SP
+ AQ) and 1,505 to the control group. The mean age of study
children at enrolment was 30.4 mo. The age and sex distributions
of children were similar in the intervention and control groups
(Table 1), as was their weight distribution. No important
differences in the proportions of wasted, stunted, or underweight
children at enrolment were observed between the groups. The
prevalence of fever at enrolment was also comparable between
groups and the proportions of children who used an ITN before
the intervention were also similar (less than 0.5%). Similar
proportions of children were allocated to the control and
intervention groups in each of the four study villages.
Treatment and Follow-up
Similar proportions of children in the intervention and control
groups received at least the first dose of the first treatment course
(77% versus 78%). However, a higher proportion of children in
the intervention than in the control group received at least the first
dose of the second and the third courses of treatment (85% versus
78% and 86% versus 78%, respectively). The main reason for not
receiving treatment was an acute illness. The numbers of children
who received a full course of treatment (three doses) at each round
were 1,055 (70%), 1,102 (73%), and 1,104 (73%) in the control
group and 1,084 (72%), 1,213 (80%), and 1,272 (84%) in the
intervention group for the first, second, and third rounds of
treatment, respectively. Use of LLINs was monitored in a
subsample of children through weekly home visits. Similar
proportions of children in the control and in the intervention
group slept under an LLIN (92.7% versus 92.8%).
Effect of IPTc on the Incidence of Clinical Malaria
169 (8.2%) children who had a positive RDT test were parasite
negative by microscopy. Incidence of malaria defined as fever or
history of fever with asexual parasitaemia $5,000/ml( p r i m a r y
endpoint) was estimated at 1.92 (95% CI 1.73–2.14) per child during
the study period in Toeghin; 2.12 (95% CI 1.92–2.36) in Niou; 1.62
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Overall the incidence of malaria was 1.3 (95% CI 1.11–1.53) in
children aged 3–11 mo; 2.50 (95% CI 2.26–2.76) in children aged
12–23 mo; 2.56 (95% CI 2.31–2.83) in children aged 24–35 mo;
1.36 (95% CI 1.19–1.56) in children aged 36–47 mo; and 1.27 (95%
CI 1.10–1.47) in children aged 48–59 mo. The incidence of clinical
Figure 1. Trial profile.
doi:10.1371/journal.pmed.1000408.g001
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episodes of clinical malaria with asexual parasitaemia of 5,000/mlo r
more were recorded in children in the control group compared with
332 episodes in children in the intervention group. 523 children had
one episode, 201 had two episodes, and 19 had three episodes in the
control group. In the intervention group, 246 children had one
episode, 43 had two episodes, and no child experienced three
episodes. The unadjusted IRR was 0.30 (95% CI 0.26–0.34)
(p,0.001), indicating a PE of 70%. Adjustment for age, sex, and
village did not alter this estimate. There was strong evidence that the
IRR varied with age (p,0.0001) with the effect of IPTc being
strongestintheyoungestchildren(3–23 mo).IPTcwithSP+AQ was
effective in reducing clinical malaria in the four study villages
(Table 2). There was weak evidence to suggest that the IRR varied
with village (p=0.06); the smallest protective effect was observed in
the village of Sao and in the remaining villages, the protective effect
was similar. Very few children werereported as not having used a net
the previous night and so whether the effect of IPTc on clinical
malaria varied with ITN use could not be examined.
Administration of IPTc delayed the time until children
experienced their first clinical attack of malaria defined as the
presence of fever or a history of fever together with P. falciparum
asexual parasitaemia at a density of 5,000 parasites/ml or more
(p,0.0001) (Figure 2).
Analysis using the secondary endpoint definition of clinical
malaria (fever or history of fever and the presence of asexual
parasitaemia of any density) showed a similar reduction
(IRR=0.29; 95% CI 0.26–0.32) (p,0.001) to the reduction
observed when clinical malaria was defined as fever or history of
fever with the presence of at least 5,000 asexual parasites/ml.
Severe malaria was observed in 13 children in the control group
and in four children in the intervention group (PE=69%; 95% CI
6%–90%) (p=0.04) (Table 3). The incidence of all-cause hospital
admissions (20 cases in the intervention group compared with 37
in the control group) was 46% lower in the IPTc arm (95% CI
7%–69%) (p=0.03) (Table 3).
Effect of IPTc on the Prevalence of Malaria Infection
The prevalence of malaria parasitaemia among children visited
at home during the intervention period was lower in the
intervention than in the control group (18.6% versus 45.8%)
(PE=59%, 95% CI 50%–67%) (p,0.001) (Table 4). A lower
prevalence of gametocytes was observed in children who received
the intervention than in children who did not (2.4% versus 10.3%;
RR=0.23; 95% CI 0.13–0.40) (p,0.001).
The overall prevalence of malaria parasitaemia was 26.4%
during the survey conducted at the end of the malaria transmission
season (6 wk after the last course of IPTc treatment); 94.2% (714)
and 1.2% (9) of these infections were single infections with P.
falciparum and P. malariae, respectively, the remainder being mixed
infections. The prevalence of malaria infection increased with age
(p,0.001) and varied between villages (unpublished data). 6 wk
after the last course of IPTc treatment, 11.4% (164) of children in
the IPTc arm had malaria parasitaemia compared to 41.5% (594)
in the control group (PE=73%; 95% CI 68%–77%) (p=0.001).
There was strong evidence that the effect of IPTc on malaria
infection varied with age (p=0.003) with the effect being strongest
in children aged 3–23 mo. The proportion of children who carried
gametocytes postintervention as assessed by microscopy was also
lower in children from the intervention arm than in the control
arm (2.0% versus 9.3%) indicating a 79% (95% CI 68%–86%)
reduction in the risk of gametocytes carriage in children who had
received IPTc (p,0.001).
Effect of IPTc on Anaemia
The prevalence of anaemia (Hb,11 g/dl) overall was high but
decreased with age, from 70% (772) in children aged 3–23 mo to
45% (809) in children aged 24–59 mo (p,0.0001) but there was
no evidence that it varied between village (p=0.42).
Hb concentration was higher in the intervention group than in
the control group at the end of the malaria transmission season
(mean Hb 11.01 g/dl [95% CI 10.94–11.08 g/dl] versus a mean
of 10.35 g/dl [95% CI 10.27–0.42 g/dl]) (p,0.001). Anaemia
(Hb,11 g/dl) was less common in children in the IPTc arm than
in the control arm (RR=0.67; PE=33%, 95% CI 25–39)
(p,0.001). 89 (6.2%) children in the control group had moderately
severe anaemia (Hb,8 g/dl) versus 39 (2.7%) children in the
intervention group (PE=56%; 95% CI 36%–70%) (p,0.001).
There were too few cases of severe anaemia (Hb,5 g/dl) to
perform any meaningful comparative analysis between the
intervention and control groups (zero and four cases, respectively).
Effect of IPTc on Anthropometric Indicators
At the end of the malaria transmission season, IPTc was
associated with a 21% reduction (95% CI 0%–35%) (p=0.05) in
the risk of wasting (Table 4). Children in the intervention group
were also less likely to be underweight (PE=16%; 95% CI 1–28)
(p=0.03). The prevalence of stunting was similar in the two groups
Table 1. Characteristics of the study children at the time of
administration of the first dose of treatment and their use of
ITNs before intervention.
Characteristics Intervention Control
Percent (n) Percent (n)
n=1,509 n=1,505
Age (mo)
3–11 15.3 (231) 16.9 (255)
12–23 23.1 (348) 21.6 (325)
24–35 20.3 (307) 21.0 (316)
36–47 22.6 (341) 20.1 (302)
48–59 18.7 (262) 20.4 (307)
Mean age 30.48 (SD =15.76) 30.45 (SD =16.32)
Sex
Male 52.3 (789) 50.5 (760)
Female 47.7 (720) 49.5 (745)
Weight (kg)
5–9 39.3 (593) 39.0 (587)
10–18 60.4 (911) 60.8 (915)
$19 0.3 (5) 0.2 (3)
Mean weight 11.05 (SD =3.01) 11.03 (SD =3.07)
Nutritional factors n=1,496 n=1,488
Wasting 11.9 (178) 11.4 (170)
Stunting 38.9 (582) 38.3 (570)
Underweight 24.6 (368) 25.3 (376)
Fever 20.0 (302) 19.9 (299)
Use of bednets n=1,428 n=1,421
Any net 0.6 (18) 0.8 (11)
Treated net 0.2 (3) 0.5 (7)
SD, standard deviation.
doi:10.1371/journal.pmed.1000408.t001
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treatment arms using data from children who were present both
at the baseline and postintervention survey indicated greater
weight gain in the intervention than in the control group (0.72 kg
versus 0.57 kg) (p,0.0001). The effect of IPTc on clinical malaria
varied in stunted and nonstunted children (p=0.0001) with PEs of
62% (95% CI 54%–69%) and 78% (95% CI 73%–81%),
respectively. No evidence of an effect modification was observed
for underweight (p=0.18) or wasting (p=0.07).
Effect of IPTc on Antimalarial Drug Resistance
The prevalence of genetic markers of resistance to SP and AQ
was assessed before the intervention in children 3–59 mo old who
were not enrolled in the trial but who lived in the same
Table 2. Effect of IPTc on the incidence of malaria, defined as fever or history of fever with 5,000 or more asexual forms of P.
falciparum per ml, by age group and locality.
Age and
Locality Intervention (SP + AQ) Control
Unadjusted IRR
(95% CI) p-Value
Adjusted IRR
(95% CI)a
PE (1 2 RR)
(95%CI) p-Value
Episodes (Child
Years)
Incidence Rate
(95%CI)
Episodes
(Child Years)
Incidence Rate
(95% CI)
Age (mo)
3–23 107 (147.4) 0.73 (0.60–0.87) 439 (127.5) 3.44 (3.13–3.78) 0.21 (0.16–0.26) ,0.001 0.21 (0.16–0.26) 79 (74–84) ,0.001
24–59 225 (231.7) 0.97 (0.85–1.11) 543 (213.7) 2.54 (2.33–2.76) 0.38 (0.32–0.44) ,0.001 0.38 (0.32–0.44) 62 (56–68) ,0.001
Overall 332 (380.3) 0.87 (0.78–0.97) 982 (341.3) 2.88 (2.70–3.06) 0.30 (0.26–0.34) ,0.001 0.30 (0.26–0.34) 70 (66–74) ,0.001
Locality
Toeghin 84 (96.4) 0.87 (0.70–1.08) 267 (85.6) 3.12 (2.77–3.52) 0.27 (0.21–0.36) ,0.001 0.27 (0.21–0.35) 73 (65–79) ,0.001
Niou 82 (87.0) 0.94 (0.76–1.17) 268 (77.4) 3.46 (3.07–3.90) 0.27 (0.21–0.35) ,0.001 0.26 (0.20–0.33) 74 (67 –80) ,0.001
Laye 73 (99.0) 0.74 (0.59–0.93) 231 (88.8) 2.60 (2.29–2.96) 0.28 (0.21–0.37) ,0.001 0.27 (0.21–0.36) 73(64–79) ,0.001
Sao 93 (97.8) 0.95 (0.78–1.16) 216 (89.5) 2.41 (2.11–2.75) 0.39 (0.30–0.50) ,0.001 0.39 (0.30–0.50) 61(50 –70) ,0.001
aIRRs were adjusted for age sex and village using random effect Cox Regression model.
PE was obtained using as follows. Note the incidence rates relate only to the three mo surveillance period are not an annual rate.
doi:10.1371/journal.pmed.1000408.t002
Figure 2. Time to first episode of clinical malaria defined as fever ($37.56C) or history of fever in the last 24 h and parasitaemia
$5,000/ml in the intervention and control arms. Kaplan-Meier survival estimates with pointwise 95% confidence bands.
doi:10.1371/journal.pmed.1000408.g002
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triple dhfr mutations at codons 51, 59, and 108 associated with
resistance to pyrimethamine or the triple dhfr plus single dhps
mutation (mutation at codon 437), associated with resistance to
sulphadoxine, were estimated at 32.6% and 25%, respectively
(Table 5). No child carried an infection with triple dhfr and dhps
mutations at codons 540 and 437. There was no evidence of a
difference in the proportions of children who carried mutant
parasites between the intervention and control groups during the
postintervention survey. However, there was an overall increase
between baseline and postintervention surveys in the proportions of
children with triple dhfr mutations only (p,0.001) and triple dhfr plus
a single dhps (codon 437) mutation (p=0.001). The proportions of
children harbouring parasites with the pfcrt-76 or pfmdr1-86
mutations were similar in the control and intervention arms and
did not increase postintervention as compared to baseline.
A small in vivo study conducted in asymptomatic children
resident in the study area in the year after the intervention study
confirmed the efficacy of the SP + AQ combination in clearing
asymptomatic P. falciparum infections (Text S4).
Adverse Events
Ten deaths were observed during the intervention period, seven
in children in the control group and three in children in the
intervention group. Verbal autopsies suggested that four deaths
(three deaths in the control group) were associated with malaria,
three with acute diarrhoea and malnutrition, two with diarrhoea
only, and that one death was due to pneumonia.
No drug-related serious adverse events were observed during
the follow-up period. The risk of itching, skin rash, diarrhoea,
drowsiness, or loss of appetite did not differ between children who
received SP plus AQ and those who received placebo (Table 6).
The proportion of children who vomited at least once during the
three courses of treatment was higher in children who received
SP + AQ, 368/1,339 (27.6%), than in children who received
placebos of SP plus AQ, 122/1,257 (9.7%). Amongst children
Table 3. Effects of IPTc on clinical malaria, defined as fever or history of fever with asexual P. falciparum parasitaemia of any
density, severe malaria, and all-cause hospital admission.
Secondary
Endpoint Intervention (SP + AQ) Control
Unadjusted
IRR (95% CI) p-Value
Adjusted
IRR
(95% CI)a
PE
(95% CI) p-Value
n episodes
Days
at Risk
Incidence
Rate
(95% CI) n episodes
Days
at Risk
Incidence
Rate
(95% CI)
Clinical malaria 416 373.6 1.11
(1.00–1.22)
1,232 325.5 3.78
(3.58–4.00)
0.29 (0.26–0.32) ,0.001 0.29
(0.26–0.32)
71 (68–74) ,0.001
Severe malaria
b 4 406.0 0.01
(0.004–0.026)
13 402.8 0.032
(0.019–0.056)
0.31 (0.10–0.94) 0.038 0.31
(0.10–0.94)
69 (6–90) 0.039
All-cause
hospital
admission
20 405.4 0.05
(0.03–0.08)
37 401.7 0.09
(0.07–0.13)
0.54 (0.31–0.92) 0.024 0.54
(0.31–0.93)
46 (7–69) 0.026
Deaths 3 406.5 7.4 { (2.4
–22.9
7 403.4 17.4{
(8.3–36.4)
c
0.43 (0.11–1.64) 0.22 0.43
(0.11–1.64)
0.57
(20.64 to 89)
0.22
aIRRs adjusted for age, sex, and village. Note the incidence rates relate only to the 3-mo surveillance period and are not an annual rate.
bSevere malaria was defined according to the WHO definition [17] ‘‘presence asexual forms of P. falciparum and any other of danger signs of severe malaria in the
absence of any other cause of illness.’’
cDeath rates per 1,000 child year.
doi:10.1371/journal.pmed.1000408.t003
Table 4. Effect of IPTc on malaria infection, anaemia, and anthropometric indicators at the end of the malaria transmission season.
Secondary Endpoint Intervention (SP+AQ) Control Unadjusted Analysis Adjusted Analysis
Percent (n) n Percent (n) n RR (95% CI) p-Value RR (95% CI) p-Value
Weekly survey of malaria infection
Proportion with parasitaemia 18.6 (133) 715 45.8 (317) 692 0.40 (0.34–0.48) ,0.001 0.41 (0.33–0.50) ,0.001
End of transmission survey
Proportion with parasitaemia 11.4 (164) 1,436 41.5 (594) 1,430 0.27 (0.23–0.32) ,0.001 0.27 (0.23–0.32) ,0.001
Proportion with anaemia (Hb,11 g/dl) 44.2 (638) 1,444 65.5 (944) 1,441 0.67 (0.63–0.72) ,0.001 0.67 (0.61–0.75) ,0.001
Proportion with moderate anaemia
(Hb,8g / d l )
2.7 (39) 1,444 6.2 (89) 1,441 0.44 (0.30–0.63) ,0.001 0.44 (0.30–0.64) ,0.001
Proportion with wasting 8.8 (122) 1,391 11.2 (156) 1,389 0.78 (0.62–0.98) 0.031 0.79 (0.65 –1.00) 0.049
Proportion with stunting 37.8 (526) 1,391 39.0 (542) 1,389 0.97 (0.88–1.06) 0.52 0.96 (0.85–1.08) 0.50
Proportion with underweight 20.8 (289) 1,391 24.7 (343) 1,389 0.84 (0.73–0.97) 0.015 0.84 (0.72–0.99) 0.034
RRs adjusted for age, sex and village using a Poisson regression generalized linear model (GLM). Wasting was defined as ,22 z-score weight for age. Stunting was
define as ,22 z-score of height for age. Underweight was defined as ,22 z-score of weight for height.
doi:10.1371/journal.pmed.1000408.t004
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risk of vomiting and the risk of vomiting decreased with age
(Table 7). The proportions of children who vomited during the
first, second, and third round of treatment were 17% (197), 15%
(184), and 13% (160), respectively, in children who received SP +
AQ. The RR for vomiting remained similar between the first
(RR=2.9), the second (RR=3.0), and the third (RR=3.3) course
of treatment in the intervention group when compared to the
control group.
Discussion
To the best of our knowledge, this is the first study to test if IPTc
provides protection against malaria in children who are already
protected by an ITN. Our results show conclusively that IPTc does
provide substantial protection against clinical malaria episodes,
severe malaria, and all-cause hospital admissions in children using
an ITN. The primary role of ITNs is to prevent mosquito bites,
thus reducing the risk of malaria infection, whereas IPTc clears
existing infections and has a prophylactic effect preventing new
blood stage infections. The high PE of IPTc in children using
ITNs may partly reflect protection from infections acquired
because of exposure to mosquitoes at night outside sleeping hours.
Coverage of ITNs was low among older children and adults in the
study area; the absolute reduction in malaria incidence due to
IPTc may have been less if coverage of ITNs in the population as a
whole had been higher. A similar additional effect of combining
chemoprevention with ITNs was observed in a community
randomised study of ITNs and chemoprophylaxis with Maloprim
(dapsone-pyrimethamine) given every 2 wk in Sierra Leone [23].
In this study, ITNs and chemoprophylaxis alone were associated
with 49% and 42% protection against malaria, respectively,
whereas the combined effect of the two interventions was 72%
(95% CI 67%–76%). Consistent findings have also been reported
from The Gambia, where seasonal chemoprophylaxis with
Maloprim protected children from malaria attacks in villages
where ITNs were being used [24].
The efficacy of IPTc against clinical attacks of malaria was a
little less in our study than that seen in Senegal [6] but very similar
to that obtained in Mali [7] and Ghana [8] in populations with a
low use of ITNs. Varying efficacy of IPTc between trials may be
explained by a number of factors including transmission intensity
and nutritional status. Our results showed that IPTc was more
beneficial to children who were not stunted. A previous study by
Danquah and collaborators [25] had reported that IPT of malaria
in infants was less effective in malnourished than in non-
malnourished infants. In our study, the impact of IPTc was more
marked in children less than 24 mo, who have yet to achieve
significant acquired immunity to malaria, than in older children, a
similar pattern to that observed in Senegal [6]. A total of 3,756
courses of IPT treatment were administered in the SP + AQ arm,
and 650 cases of malaria were averted, thus 5.8 IPT administra-
tions were needed to prevent one episode of malaria.
The reduction in the prevalence of anaemia seen in our study is
consistent with the results of the study conducted in Hohoe,
Ghana [8] where a 45% reduction in anaemia was observed in
children who received IPTc with AS plus AQ monthly, and a 30%
reduction was seen in children who received bimonthly IPTc with
Table 5. Percentage of children carrying parasites harbouring genetic mutation associated with resistance to SP and AQ at
baseline and 6 wk postintervention in intervention and control arms.
Genetic Mutation
Baseline, n=132,
Percent (n) Postintervention
IPTc, n=114,
Percent (n)
Placebo, n=122,
Percent (n)
Overall postintervention,
n=236, Percent (n)
Baseline versus
postintervention, p-Value
Triple dhfr mutation (51-59-108) 32.6 (43) 50 (57) 53.3 (65) 51.7 (122) ,0.001
Triple dhfr single dhps (437) 25.0 (33) 40.4 (46) 44.3 (54) 42.4 (100) 0.001
Triple dhfr/double dhps (437–540) 0 (0) 0.9 (1) 0.0 (0) 0.4 (1) 0.45
Pfcrt-76 63.9 (83) 60.5 (69) 61.5 (75) 61.0 (144) 0.72
Pfcrt-76/pfmdr1-86 20.5 (27) 19.3 (22) 19.7 (24) 19.5 (46) 0.82
doi:10.1371/journal.pmed.1000408.t005
Table 6. Percentage of children with adverse events on at
least one occasion during the three rounds of treatment in
intervention and control arms.
Adverse
Event IPTc Placebo RRs (95% CI) p-Value
Percent (n/n) Percent (n/n)
Fever 13.4 (179/1,339) 14.9 (187/1,257) 0.90 (0.74–1.11) 0.33
Vomiting 27.6 (368/1,339) 9.7 (122/1,257) 2.83 (2.31–3.47) ,0.001
Drowsiness 0.1 (1/1,339) 0.1 (1/1,257) 0.94 (0.06–15.0) 0.96
Itching 2.2 (30/1,339) 2.4 (30/1,257) 0.94 0.56–1.56) 0.80
Diarrhoea 7.2 (96/1,339) 7.0 (88/1,257) 1.02 (0.77–1.37) 0.86
Skin rash 1.5 (20/1,339) 1.6 (20/1,257) 0.94 (0.50–1.74) 0.84
Coughing 5.2 (70/1,339) 5.9 (74/1,257) 0.92 (0.66–1.27) 0.60
Loss of
appetite
1.4 (5/1,339) 1.3 (3/1,257) 1.51 (0.36–6.34) 0.57
doi:10.1371/journal.pmed.1000408.t006
Table 7. Risk of vomiting by age in children who received SP
+ AQ.
Age group (mo) Percent (n/m) RR (95% CI) p-Value
3–11 54.5 (114/209) 9.9 (5.6–17.2) ,0.001
12–24 38.7 (117/302) 7.0 (4.0–12.2) ,0.001
24–35 28.6 (75/262) 5.2 (2.92–9.2) ,0.001
36–47 14.5 (48/309) 2.8 (1.5–5.1) 0.001
48–59 5.5 (14/253) 1 —
doi:10.1371/journal.pmed.1000408.t007
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in a detectable reduction in anaemia in Senegal [6]. It is likely that
the fraction of anaemia attributable to malaria differs between
settings and this fraction is likely to be lower in areas with lower
transmission intensity such as Senegal. Modest reductions were
observed in the proportion of wasted and underweight children
after IPTc administration, but there was no effect on stunting. The
lack of an effect on stunting is perhaps not surprising as this is
generally held to be a measure of chronic undernutrition, which is
less likely to change substantially over the period of follow-up
reported in this paper than indicators of acute undernutrition.
IPTc increased the mean weight gain during the rainy season as
previously reported in a study that also demonstrated an increase
in subcutaneous fat reserves in Senegalese children who received
IPTc with SP plus AS [26].
The study was not powered to detect an impact on cases of
severe malaria, hospital admissions, or deaths. However, encour-
aging results were found with a reduction in deaths, overall
hospital admissions, and severe malaria in children who received
IPTc with differences in cases of severe malaria and hospital
admissions being statistically significant. Thus, it seems likely that
if IPTc was widely deployed in areas with a similar pattern of
malaria transmission to that of the study area it would have a
significant impact on severe morbidity and mortality from malaria.
This supposition is supported by the results of an earlier study
conducted in The Gambia [27], which showed that chemopro-
phylaxis with Maloprim given fortnightly during the rainy season
reduced overall mortality in children aged less than 5 y by about
40%.
We monitored adverse events over 4 d during each course of
treatment and detected no serious adverse events related to the
study drugs, which were reasonably well tolerated and safe.
However, we observed a higher risk of vomiting in the intervention
group, as has been reported in previous IPTc studies that used
drug combinations containing AQ [8,13,28]. Unlike the Hohoe
study, the frequency of vomiting did not decrease with subsequent
courses of IPTc. Our data showed a considerably higher risk of
vomiting in younger children. Vomiting induced by AQ was not a
significant deterrent to the use of SP plus AQ because compliance
with the full course of treatment was higher in children who
received IPTc than in those who received placebo. Nevertheless,
the acceptability of SP plus AQ for IPTc would be improved if this
problem could be overcome. There are at least two possible ways
that this might be accomplished. A recent study undertaken in
Senegal showed that the frequency of vomiting following the use of
AQ containing combinations for IPTc is dose dependent [29].
Thus, one possibility would be to adjust the AQ content of tablets
used for IPTc, allowing the optimum spread of dose per kg body
weight for each weight group and ensuring that as few as possible
children are overdosed. A second approach would be to produce a
formulation of AQ that was more palatable than standard tablets.
A number of concerns have been raised about the adoption of
IPTc as a malaria control strategy. These include the possibility
that IPTc will encourage the spread of resistance to the drugs used
for IPTc. We observed an increase in the proportion of children
harbouring genetic mutations associated with resistance to SP at
the end of the malaria transmission season compared with the
preintervention period but not in the prevalence of genetic
mutations associated with resistance to chloroquine. However, in
contrast to the findings of a study conducted in Senegal [6], we
found no difference in the prevalence of resistance markers
between intervention and control groups. This difference between
studies might be due to the higher level of malaria transmission in
the study area compared with Senegal, resulting in a higher rate of
exchange of parasite strains between the two treatment groups and
the rest of the population. An overall increase in the prevalence of
drug resistance markers over the course of the malaria
transmission season has been seen previously in areas of seasonal
malaria transmission in the absence of any chemopreventive
strategy [30], probably reflecting the selection pressure of an
overall increase in the use of antimalarials for the treatment of
febrile illnesses at this time of the year. However, we cannot
exclude the possibility that the use of IPTc made some
contribution to the overall increase in the prevalence of dhfr
resistance markers seen at the end of the transmission season and
sustained implementation of IPTc would inevitably increase drug
pressure, a risk that would need to be balanced against the marked
benefit that can result from this intervention. This risk can be
reduced by using a drug combination rather than a single drug for
IPTc and by using a different drug combination for IPTc than the
one used for first-line treatment of symptomatic malaria.
Another concern is that IPTc might interfere with the
development of naturally acquired immunity to malaria, leading
to an increase in the incidence of malaria in children after they
move out of the age range in which IPTc is given. Administration
of IPTc for 1 y did not lead to an increase in the incidence of
clinical attacks of malaria in the following year in children in
Senegal [6] or in older children in Ghana [8]. Nevertheless, we are
investigating this possibility in the current study and the
surveillance procedure described in this paper was reestablished
during the 2009 malaria transmission season to look for any
evidence of ‘‘rebound’’ malaria. Even if no increase in risk is
found, this does not exclude the possibility that IPTc could
significantly impair the development of natural immunity if
administered to children for several consecutive years and this
would have to be monitored carefully if IPTc is implemented as a
malaria control strategy.
Another major concern is whether IPTc could be delivered on a
large scale. As this was an efficacy trial, medications were given
under the control of project staff and this study did not address the
issue of the implementability of IPTc. This issue has been
addressed in a previous study undertaken in Ghana [31] and a
study that has investigated two possible modes of delivery in The
Gambia, use of immunisation trekking teams or community
volunteers is described in an accompanying paper [32]. A study of
the feasibility and safety of large scale implementation of IPTc
with SP + AQ is currently underway in Senegal.
A notable feature of this study was the high incidence of malaria
in children in the control group who slept under an LLIN: 982 of
1,505 children experienced a clinical attack during the 3-mo
observation period that corresponded to the peak malaria
transmission season. A number of possible reasons for this result
have been considered. Home visits indicated that more than 90%
of the children had used their LLIN the previous night so that
failure to use a bednet is unlikely to have been a major factor. It is
possible that some children experienced mosquito bites before they
retired to bed but this is less likely to be a problem than in older
children or adults. LLINs (PermaNet) were obtained from a well-
established manufacturer (Vestergaard). Checks on the deltame-
thrin content of ITNs obtained at the end of the malaria
transmission season showed protective levels of deltamethrin in
most samples and this was confirmed by bioassays (Text S7).
However, some kdr-mediated resistance to pyrethroids was found
(Text S7). Although the entomological inoculation rate (EIR) (34
infective bites per person per year) was significantly less than had
been recorded in the same area 6 y previously, perhaps in part due
to the use of LLINs, this was sufficient to sustain a high clinical
attack rate in young children. LLINs were provided only to
Intermittent Preventive Treatment
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their mothers, and their older siblings, only about a third of the
population were protected by an LLIN. To obtain maximum
benefit from ITNs in high transmission settings such as this,
universal coverage with ITNs is probably required.
Conclusion
IPT of malaria with SP plus AQ was safe and provided
substantial additional protection against severe and uncomplicated
malaria to children who slept under an LLIN. There is now strong
evidence to support the integration of IPTc into malaria control
strategies in areas of seasonal malaria transmission. Further
research is needed to identify alternative drugs as the long-term
use of SP for IPTc is uncertain.
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Background. Malaria accounts for one in five of all
childhood deaths in Africa and of the one million annual
malarial deaths world-wide, over 75% occur in African
children under 5 years old. Malaria also causes severe
morbidity in children, such as anemia, low birth weight, and
neurological problems, which compromise the health and
development of millions of children living in malaria endemic
areas. As much of the impact of malaria on African children
can be effectively prevented, significant efforts have been
made in recent years to improve malaria control, such as the
implementation of intermittent preventive treatment of
malaria.
Intermittent preventive treatment (IPT) involves administra-
tion of antimalarial drugs at defined time intervals to
individuals, regardless of whether they are known to be
infected with malaria, to prevent morbidity and mortality. IPT
was initially recommended for pregnant women and recently
this strategy was extended to include infants (IPTi). Now,
there is also IPT of malaria in children (IPTc), which is
designed to protect against malaria during the high malaria
transmission season.
Why Was This Study Done? Large clinical trials have
shown that IPTc involving the administration of two to three
doses of an antimalarial drug (sulphadoxine pyrimethamine
[SP] and artesunate [AS] or amodiaquine [AQ]) during the
high malaria transmission season effectively reduces the
incidence of malaria. However, these studies were conducted
in countries where the use of insecticide-treated bednets—
an intervention that provides at least 50% protection against
morbidity from malaria and is the main tool used for malaria
control in most of sub-Saharan Africa—was relatively low.
Therefore, it is unclear whether IPTc will be as effective in
children who sleep under insecticide-treated bednets as has
been previously shown in communities where insecticide-
treated bednet usage is low. So to determine the answer to
this important question, the researchers conducted a
randomized, placebo-controlled trial of IPTc with SP + AQ
(chosen because of the effectiveness of this combination in a
pilot study) in children who slept under an insecticide-
treated bednet in an area of seasonal malaria transmission in
Burkina Faso.
What Did the Researchers Do and Find? The researchers
enrolled 3,014 eligible children aged 3–59 months into a
randomized double-blind, placebo-controlled trial during the
2008 malaria transmission season in Burkina Faso. All
children were given a long-lasting insecticide-treated
bednet at the start of the study with instructions to their
family on the correct use of the net. Children were then
randomized into two arms—1,509 were allocated to the
intervention group and 1,505 to the control group—to
receive three courses of IPTc with SP plus AQ or placebos
given at monthly intervals during the peak malaria
transmission season. The researchers monitored the
incidence of malaria throughout the malaria season and
also monitored the use of long-lasting insecticide-treated
bednets throughout the study period. In addition,
researchers conducted a cross-sectional survey in 150
randomly selected children every week and in every child
enrolled in the trial 6 weeks after the last course of IPTc, to
measure their temperature, height and weight, and blood
hemoglobin and parasite count levels.
The number of children who slept under their long-lasting
insecticide-treated bednet was similar in both arms. During
the intervention period, the researchers found that the
incidence of clinical malaria (defined as fever or a history of
fever and the presence of at least 5,000 asexual forms of P.
falciparum per microliter) was 2.88 in the control arm versus
0.87 in the intervention arm—giving a protective efficacy of
70%. There were 13 cases of severe malaria in the control
arm and four in the IPTc arm—a 69% reduction in incidence.
Additionally, all-cause hospital admission rate was reduced
by 46%. At the end of the malaria transmission period, IPTc
reduced the proportion of children infected with malaria
parasites by 73% and reduced anemia by 33%. In addition,
IPTc appeared to reduce the risk of wasting (risk ratio =0.79)
and of being underweight (risk ratio =0.84). However,
children who received IPTc were almost three times more
likely to vomit than children who received placebo but there
were no drug-related serious adverse events.
What Do These Findings Mean? The results of this study
show that in peak malarial transmission season in Burkina
Faso, IPTc provides substantial additional protection against
episodes of clinical malaria, severe malaria, and all-cause
hospital admissions in children sleeping under long-lasting
insecticide-treated bednets. In addition, intermittent
preventive treatment of malaria with SP plus AQ appears
to be safe for use in children.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000408.
N This topic is further discussed in two PLoS Medicine
research articles: Dicko et al. and Bojang et al., and in a
PLoS Medicine Perspective by Beeson
N Roll Back Malaria has information about malaria in children,
including intervention strategies
N UNICEF also provides comprehensive information about
malaria in children
N The Intermittent Preventive Treatment in Infants Consor-
tium (ipti) provides information on intermittent preventive
treatment in infants
N Roll Back Malaria has an information sheet on insecticide-
treated bednets
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